Floatz logo

Vinorelbine

Progesterone Receptor-negative Breast Cancer

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityPhase 2Dormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Progesterone Receptor-negative Breast Cancer cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2BB
Veliparib
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2BB
Irinotecan
University of Washington
Phase 2BB
FILGRASTIM
University of Washington
Phase 2B

View all 32 →

Same molecule, other indications

Vinorelbine is also rated in:

HER2 positive breast carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Recurrent Breast CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →